Zai Lab Limited is a patient-focused, innovative, commercial-stage, global biopharmaceutical company. It is listed on both the Nasdaq Global Market in the United States and the Main Board of the Stock Exchange of Hong Kong Limited (Nasdaq: ZLAB; HKEX: 9688).

On November 19, 2024, Zai Lab completed a follow-on offering of 9,019,607 American Depositary Shares, including the ADSs offered upon the full exercise of the underwriters’ over-allotment option, on the Nasdaq Global Market, raising total gross proceeds of approximately USD 230 million. The proceeds will primarily be used to supplement funding for Zai Lab’s business and operations.

Fangda acted as Zai Lab’s PRC legal counsel, fully participated in the overseas follow-on offering transaction and assisted Zai Lab in its filings with the China Securities Regulatory Commission. The team was led by partners Jeffrey Ding and Yvette Liu. Team members included Travis Xu, Li Menyuan and Zheng Chunyuan.